Patent License Agreement Sample Contracts

PATENT LICENSE AGREEMENT – EXCLUSIVE
Patent License Agreement • December 6th, 2024

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).

PATENT LICENSE AGREEMENT
Patent License Agreement • June 6th, 2025 • Rhode Island

This Patent License Agreement (referred to as the “Agreement”) is entered into as of [INSERT DATE] (the “Effective Date”), by and between [LICENSOR COMPANY NAME], a [STATE/COUNTRY] [corporation/LLC/other entity type] with its principal place of business at [ADDRESS] (the “Licensor”), and [LICENSEE COMPANY NAME], a [STATE/COUNTRY] [corporation/LLC/other entity type] with its principal place of business at [ADDRESS] (the “Licensee”). The Licensor and the Licensee may be referred to individually as a “Party” and collectively as the “Parties”.

PATENT LICENCE AGREEMENT 4
Patent License Agreement • December 29th, 2020
PATENT LICENSE AGREEMENT n° C-00061906
Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)

IP is owner of patents and patent applications relating to a method of homologous recombination. IP has already granted exploitation rights for these patents and patent application to third parties for specific applications and now wishes to share this technology with a new industrial partner.

Patent License Agreement for Startups Agreement No.
Patent License Agreement • October 31st, 2024 • Texas

This Patent and Technology License Agreement (“Agreement”) is between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas at El Paso (“UTEP”), a component institution of System (Board and UTEP together “Licensor”) and [Company Name] a [State] corporation with its principal place of business at [Company Address] (“Licensee”) (collectively, “Parties”, or singly, “Party”).

EX-10.13 5 dex1013.htm LICENSE AGREEMENT WITH UNIVERSITY OF PENNSYLVANIA EXECUTION VERSION [CONFIDENTIAL TREATMENT REQUESTED] /*/ INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED...
Patent License Agreement • May 5th, 2020 • Pennsylvania

This Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Aegerion Pharmaceuticals, Inc, a Delaware corporation (“Company”). This Agreement is effective on May 19, 2006 (the “Effective Date”).

SISVEL WIRELESS LICENSE AGREEMENT
Patent License Agreement • December 17th, 2024

This Patent License Agreement (“Agreement”) is entered into by and between SISVEL INTERNATIONAL S.A., a company duly incorporated under the laws of Luxembourg with an office at Immeuble Cubus C2, 2 rue Peternelchen, L-2370 Howald, Grand Duchy of Luxembourg, (“Sisvel”), and XYZ , a company duly incorporated under the laws of , with its principal office at , (“Licensee”).

EX-10.16 41 d358280dex1016.htm PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the...
Patent License Agreement • May 5th, 2020 • District of Columbia

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:

Contract
Patent License Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations • District of Columbia

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Certain identified information has been omitted from this exhibit because it is both (i) not material and brackets (“[…***…]”) in this exhibit.*** PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent...
Patent License Agreement • January 16th, 2024 • Kyverna Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Shipping Information), Appendix G (Example Royalty Report), and Appendix H (Royalty Payment Options).

Contract
Patent License Agreement • May 5th, 2020 • New York

EX-10.6 13 exhibit106s-1.htm EXHIBIT 10.6 Exhibit 10.6 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. PATENT LICENSE AGREEMENT THIS PATENT LICENSE AGREEMENT (the “Agreement”) is made effective as of January 1, 2017 (the “Effective Date”), by and between Keygene N.V. (“KeyGene”), a company organized and existing under the laws of The Netherlands and having its registered offices at Agro Business Park 90, 6708 PW Wageningen, The Netherlands, and Guardant Health, Inc., a company incorporated under the laws of the State of Delaware, and having an address at 505 Penobscot Drive, Redwood City, CA 94063 (“Licensee”) and relates to KeyGene Technology as defined hereinafter. KeyGene and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties.” BACKGROUND WHEREAS, KeyGene is a biotechnology company acti

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT-NONEXCLUSIVE COVER PAGE
Patent License Agreement • December 28th, 2011 • Mri Interventions, Inc. • Surgical & medical instruments & apparatus • District of Columbia

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:

Page 73 TITLE 35—PATENTS § 207
Patent License Agreement • November 6th, 2019

agreement the invention was made upon a show- ing by the small business firm, nonprofit organi- zation, or assignee that reasonable but unsuc- cessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the cir- cumstances domestic manufacture is not com- mercially feasible.

PATENT LICENSE AGREEMENT by and between TECHNIPFMC PLC AND TECHNIP ENERGIES N.V. Dated as of February 15, 2021
Patent License Agreement • March 25th, 2022 • Technip Energies N.V. • Services-engineering services • New York
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE
Patent License Agreement • March 22nd, 2024

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks), Appendix E (Commercialization Plan). Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).

PATENT LICENSE AGREEMENT
Patent License Agreement • May 23rd, 2005 • SmartMetric, Inc. • Miscellaneous manufacturing industries

AGREEMENT made and entered into as of the 1st day of August 2004, with revisions dated December 33, 2004 by and between Applied Cryptology, Inc., a Nevada corporation having its principal offices at [address] (the “Licensor”), and SmartMetric, Inc., a Nevada corporation having its principal offices at 67 Wall Street, Level 22, New York, New York 10005 (the “Company”).

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT —EXCLUSIVE COVER PAGE
Patent License Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations • District of Columbia

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE
Patent License Agreement • December 6th, 2024

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).

Portions of this exhibit were omitted and filed separately with the Secretary of the Securities and Exchange Commission pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2...
Patent License Agreement • July 7th, 2010 • Vishay Precision Group, Inc. • Electronic components & accessories • New York

This non-exclusive Patent License Agreement (“Agreement”) is entered into as of July 6, 2010 (the “Effective Date”), by and between Vishay Dale Electronics, Inc., a Delaware corporation (“Licensor”), and Vishay Precision Group, Inc. a Delaware corporation ("Licensee").

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT — EXCLUSIVE COVER PAGE
Patent License Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations • District of Columbia

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:

BACKGROUND
Patent License Agreement • July 2nd, 2003 • Interdigital Communications Corp • Patent owners & lessors • Delaware
Exhibit 10.10 PATENT LICENSE AGREEMENT
Patent License Agreement • January 31st, 2001 • Wavesplitter Technologies Inc • Semiconductors & related devices • California
EX-10.2 3 d150860dex102.htm EX-10.2 CONFIDENTIAL PORTIONS OMITTED AGREEMENT
Patent License Agreement • May 5th, 2020 • Washington

This Agreement (“Agreement”) is entered into as of October 5, 2010 (the “Effective Date”) by and among Digimarc Corporation, an Oregon corporation, with an address at 9405 SW Gemini Drive, Beaverton, OR 97008 (“Digimarc”), Invention Law Group, P.C. (“ILG”) and IV Digital Multimedia Inventions, LLC (“DMI” and together with ILG, the “IV Entities”).

PATENT LICENSE AGREEMENT AGT. NO.
Patent License Agreement • April 10th, 2024 • Texas

Licensor owns rights to the Licensed Patents. Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Licensed Patents. Licensor has determined that such use, development, and commercialization of the Licensed Patents is in the public’s best interest and is consistent with Licensor’s educational and research missions and goals. Licensor desires to have the Licensed Patents developed and used for the benefit of Licensee, the inventors, Licensor, and the public.

PATENT LICENSE AGREEMENT
Patent License Agreement • July 6th, 2020 • District of Columbia

This Agreement is entered into between the U.S. Government, as represented by the U.S. Department of Agriculture, Agricultural Research Service (hereinafter referred to as “USDA”) and (company name), a (state) corporation having offices at (street address, city, and state) (hereinafter referred to as “COMPANY”).

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PATENT...
Patent License Agreement • June 20th, 2025 • TheRas, Inc. • Pharmaceutical preparations

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).

PATENT LICENSE AGREEMENT For NanoPulse Technology
Patent License Agreement • May 3rd, 2016 • Pulse Biosciences, Inc. • Surgical & medical instruments & apparatus • California
EX-10 2 ex10-20.htm PATENT LICENSE AGREEMENT Execution Copy PATENT LICENSE AGREEMENT BETWEEN POLYMEDIX, INC. AND THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA PATENT LICENSE AGREEMENT
Patent License Agreement • May 5th, 2020 • Pennsylvania

This Patent License Agreement (this “Agreement”) is made on January 3, 2003 (the “Effective Date”), by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3160 Chestnut Street, Suite 200, Philadelphia, Pennsylvania 19104-3147 (“Penn”), and Polymedix, Inc., a Delaware corporation (“Licensee”), with its principal offices at 5 Radnor Corporate Center, 100 Matsonford Road, Suite 520, Radnor, PA 19087.

EX-10.10 12 d373760dex1010.htm EX-10.10 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT — EXCLUSIVE COVER PAGE For PHS internal use only:...
Patent License Agreement • May 5th, 2020 • District of Columbia

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:

PATENT LICENSE AGREEMENT
Patent License Agreement • May 12th, 2021

[insert name], a company established and existing under the laws of [insert country], commercial registry code [insert code], located at [insert address] (Licensor), represented by [insert position and name], and